Calcium polycarbophil
Identification
- Name
- Calcium polycarbophil
- Accession Number
- DB14684
- Description
Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.
Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Calcium polycarbophil
- Polycarbophil calcium
- Polycarbophil, calcium
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Polycarbophil is used to treat constipation and to help maintain regular bowel movements.
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.
- Mechanism of action
It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.
- Absorption
Calcium polycarbophil is not absorbed from the intestine.
- Volume of distribution
Calcium polycarbophil is not absorbed from the intestine.
- Protein binding
Calcium polycarbophil is not absorbed from the intestine.
- Metabolism
Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.
- Route of elimination
Excreted in feces.
- Half-life
Calcium polycarbophil is not absorbed from the intestine.
- Clearance
Calcium polycarbophil is not absorbed from the intestine.
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium polycarbophil. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Calcium polycarbophil. Acetyldigitoxin Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin. Aclidinium The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aclidinium. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil. Alfacalcidol The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Alfacalcidol. Alfentanil The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Alloin. Amantadine The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Calcium polycarbophil. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take with a full glass of water.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Active Moieties
Name Kind UNII CAS InChI Key Calcium salt SY7Q814VUP 7440-70-2 OYPRJOBELJOOCE-UHFFFAOYSA-N Polycarbophil salt W25LM17A4W 9003-97-8 Not applicable - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Best Choice Tablet, film coated 625 mg/1 Oral Best Choice (Valu Merchandisers Company) 2019-04-16 Not applicable US 
Calcium Polycarbophil Tablet, film coated 625 mg/1 Oral Cardinal Health 2020-11-18 Not applicable US Calcium Polycarbophil 625 mg Tablet 625 mg/1 Oral REMEDYREPACK INC. 2018-10-05 2020-05-27 US Calcium Polycarbophil 625 mg Tablet 625 mg/1 Oral REMEDYREPACK INC. 2016-10-10 2018-09-05 US Calcium Polycarbophil 625 mg Tablet 625 mg/1 Oral Reliable 1 Laboratories LLC 2015-11-01 Not applicable US Care One Fiber Tablet, film coated 625 mg/1 Oral American Sales Company 2004-03-30 2013-02-22 US Equalactin - Tab 625mg Tablet Oral Numark Laboratories, Inc. 1996-12-31 2009-07-31 Canada 
Equalactin Laxative Tablet 625 mg/1 Oral Numark Brands, Inc 1986-11-21 Not applicable US Equate fiber therapy Tablet, film coated 625 mg/1 Oral Walmart Stores 1996-11-05 2015-11-19 US Fiber Tablet, film coated 625 mg/1 Oral Western Family Foods 1998-01-19 2016-12-08 US
Categories
- ATC Codes
- A06AC08 — Polycarbophil calcium
- Drug Categories
- Alimentary Tract and Metabolism
- Antidiarrheals
- Bulk-Forming Laxatives
- Calcium Salts
- Compounds used in a research, industrial, or household setting
- Dental Materials
- Drug Carriers
- Drugs for Constipation
- Gastrointestinal Agents
- Laxatives
- Macromolecular Substances
- Phosphate Binder
- Plastics
- Polymers
- Resins, Synthetic
- Classification
- Not classified
Chemical Identifiers
- UNII
- 8F049NKY49
- CAS number
- 126040-58-2
References
- General References
- Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [PubMed:6765389]
- Monograph [Link]
- webmd [Link]
- External Links
- Wikipedia
- Polycarbophil_calcium
- AHFS Codes
- 56:12.00 — Cathartics and Laxatives
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Treatment HER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Leptomeningeal Carcinomatosis / Leptomeningeal Metastases / Tumors Metastatic to Brain 1 Not Available Completed Treatment Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 500 mg/1 Tablet, film coated Oral 625 mg/1 Tablet Oral 625 mg/1 Capsule Oral 625 mg/1 Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on September 06, 2018 02:00 / Updated on April 17, 2021 10:37